Skip to main content
TipRanks
Go Ultimate75% OFF

Fortress Biotech (FBIO) AI Stock Analysis

1,597 Followers
FBIO

Fortress Biotech

(NASDAQ:FBIO)

Select Model
Rating:64Neutral
Price Target:$2.00▲(6.38% Upside)
Action:reiterated
Date:11/15/26

The score is driven primarily by improving financial fundamentals (strong TTM cash generation and reduced leverage) but tempered by concerns about earnings quality and historical volatility. Valuation appears very inexpensive based on the low P/E, while the latest earnings call was broadly constructive on product momentum and 2027 access tailwinds. Technicals are the main drag, with the stock trading below key moving averages and negative MACD.

Positive Factors
Emrosi adoptionGrowing prescriptions, prescriber count, and refill rates indicate expanding physician adoption and patient persistence for Emrosi. This supports a more durable commercial base, improves the opportunity to scale revenue, and may strengthen the product’s position in rosacea treatment over the next several quarters.
Negative Factors
Earnings qualityNegative EBIT means reported net income does not yet reflect stable core operating profitability. The gap between earnings and operating performance raises durability concerns, because future results may depend on non-recurring or non-operating items rather than repeatable commercial economics.

Fortress Biotech (FBIO) vs. SPDR S&P 500 ETF (SPY)

-40%-20%0%20%40%60%80%FBIO-29.59%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$62.70M
Dividend Yield
―
Average Volume (3M)
286.61K
Price to Earnings (P/E)
0.6
Beta (1Y)
0.87
Revenue Growth
12.34%
EPS Growth
―
Country
US
Employees
78
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Fortress Biotech Business Overview & Revenue Model

Company Description

Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. The...

Fortress Biotech Earnings Call Summary

Earnings Call Date:Nov 13, 2026(Q3-2026)|% Change Since:-5.53%|Next Earnings Date:May 16, 2021
Earnings Call SentimentPositive

The call was strongly positive overall. Management highlighted accelerating Emrosi prescriptions, expanding prescriber adoption, strong refill rates, favorable clinical and safety data, improving payer access, positive EBITDA and a narrowing GAAP loss. The main challenges were the remaining GAAP loss, a lower cash balance, a one-time vendor settlement, temporary prescription volatility following the copay change, ongoing formulary expansion and uncertainty around the timing of 2027 benefits and guidance.

Positive Updates

Q3 Revenue and Product Sales Growth
Total revenue was $19 million compared to $15 million in the third quarter of 2025, with management reporting an 8% period-over-period increase. Net product sales increased 11% year-over-year, primarily driven by continued commercial demand for Emrosi, which generated $9 million in net revenue.

Negative Updates

GAAP Net Loss Remained
Despite the improvement from the prior year, the company still reported a GAAP net loss of $1.3 million, or $0.05 per basic and diluted share, for the third quarter.

Company Guidance

Management expects Emrosi’s key metrics to “continue to trend positively in the coming quarters,” with ASP to “trend higher in the coming quarters”; a national formulary plan covering over 25 million lives is expected to take effect at the beginning of 2027, with impact “beginning in Q1,” and management expects an “upward trend on ASP and improvement in gross to net as the quarters progress in '27.” High-quality coverage was described as 40% of commercial lives, or about 170 million, 180 million lives, with additional formularies expected to come online in 2027; SG&A as a percentage of revenue is expected to be “consistent or a little bit lower,” or to “decrease a little bit or stay consistent.” Management is “probably going to be somewhat apprehensive here in the first half of next year to give any particular guidance,” although “it certainly will be going up in our estimation”; the 5 new representatives hired with a July 1 start are expected to have “a good 2 quarters” to ramp, and prescription volume following the copay change may take “anywhere from 4 to 8 weeks” to recover, with December expected to be “a very good month.”

Fortress Biotech Financial Statement Overview

Summary

TTM results show a notable inflection with strong revenue growth (+223%) and very strong free cash flow (~$125.7M), alongside improved leverage (debt-to-equity ~0.24). However, profitability quality is a key risk: EBIT remains negative and the unusually high net/EBITDA margins suggest meaningful non-recurring or non-operating drivers, and the multi-year history includes recurring losses and negative cash flow, raising durability concerns.

Income Statement

58Neutral

Balance Sheet

66Positive

Cash Flow

72Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue69.99M63.26M57.67M84.51M75.74M68.79M
Gross Profit44.21M42.34M36.80M61.62M44.97M36.71M
EBITDA142.71M-20.16M-104.49M-135.72M-193.69M-146.17M
Net Income100.12M6.82M-46.00M-60.64M-86.58M-64.70M
Balance Sheet
Total Assets280.21M185.55M144.22M167.53M294.30M396.50M
Cash, Cash Equivalents and Short-Term Investments152.19M79.38M57.26M80.93M178.27M305.74M
Total Debt38.95M74.30M75.96M84.66M127.34M74.98M
Total Liabilities103.19M123.36M145.87M165.94M244.28M170.63M
Stockholders Equity160.00M49.87M22.74M22.54M41.72M108.67M
Cash Flow
Free Cash Flow125.75M-65.78M-95.19M-136.32M-182.46M-132.89M
Operating Cash Flow125.83M-65.78M-80.19M-128.22M-179.40M-116.54M
Investing Cash Flow-86.00K10.12M-15.00M-2.10M-22.93M40.51M
Financing Cash Flow-59.78M77.44M70.64M32.74M75.32M148.99M

Fortress Biotech Technical Analysis

Technical Analysis SentimentNegative
Last Price1.88

Price Trends

50DMA2.14Negative
100DMA2.58Negative
200DMA2.71Negative

Market Momentum

MACD-0.05Negative
RSI42.47Neutral
STOCH64.84Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FBIO, the sentiment is Negative. The current price of 1.88 is below the 20-day moving average (MA) of 1.93, below the 50-day MA of 2.14, and below the 200-day MA of 2.71, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 42.47 is Neutral, neither overbought nor oversold. The STOCH value of 64.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FBIO.

Fortress Biotech Risk Analysis

Fortress Biotech disclosed 69 risk factors in its most recent earnings report. Fortress Biotech reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We have historically relied in part on sales of our common stock and other securities to fund our operations, and our future ability to obtain additional capital through stock sales or other securities offerings may be more costly than in the past, or may not be available to us at all.Q3, 2024
2.We have paused dividend payments on our Series A Preferred Stock and may not be able to resume payment of dividends on our Series A Preferred Stock in the future if we have insufficient cash or available "surplus" as defined under Delaware law to make such dividend payments.Q3, 2024
3.Fluctuations in interest rates may negatively impact the rate of return that we realize on the investment securities that we hold.Q3, 2024

Fortress Biotech Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

FBIO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
FBIOFBIO64Neutral$62.70M0.6574.69%―12.34%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CVMCVM42Neutral$22.51M-0.50-202.14%――73.69%
EQEQ42Neutral$106.20M-7.32-37.33%―-100.00%71.65%
UNCYUNCY41Neutral$98.89M-2.12-88.81%――43.63%

* Healthcare Sector Average

Performance Comparison

0%100%200%FBIOCVMXBITEQUNCYDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
FBIO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FBIOFortress Biotech Inc1.88-0.73-27.97%
CVMCel-sci1.28-5.22-80.31%
XBITXBiotech Inc.1.96-0.51-20.65%
EQEquillium1.290.2422.86%
UNCYUnicycive Therapeutics, Inc.3.55-2.22-38.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 15, 2026